Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 9/20 | 0.42 |
| ▸ | MMP9 | P14780 | 9/20 | 0.42 |
| ▸ | MMP13 | P45452 | 8/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 4/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16670607 | 1.00 | MMP1 (0.42) | MMP1MMP9MMP13ADAM17HCRTR1 | |
| SCHEMBL16670467 | 0.91 | MMP2 (0.42) | MMP1MMP9MMP2MMP8NAMPT | |
| SCHEMBL16670470 | 0.91 | MMP2 (0.42) | MMP1MMP9MMP2MMP8NAMPT | |
| SCHEMBL16670298 | 0.90 | FPR2 (0.47) | MMP1MMP9MMP2MMP8USP30 | |
| SCHEMBL16670299 | 0.90 | FPR2 (0.47) | MMP1MMP9MMP2MMP8USP30 | |
| SCHEMBL16670072 | 0.85 | KMT2A (0.42) | MMP1MMP9NLRP3MMP2MMP8 | |
| SCHEMBL16670070 | 0.85 | KMT2A (0.42) | MMP1MMP9NLRP3MMP2MMP8 | |
| SCHEMBL16670286 | 0.85 | MMP1 (0.38) | MMP1MMP9MMP2MMP8ALDH1A1 | |
| SCHEMBL16670289 | 0.85 | MMP1 (0.38) | MMP1MMP9MMP2MMP8ALDH1A1 | |
| SCHEMBL16669943 | 0.82 | MMP9 (0.51) | MMP1MMP9MMP2MMP8GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2016-09-08 | — | — | US | disclosed |
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2016-09-08 | — | — | US | disclosed |
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2016-09-08 | — | — | US | disclosed |
| EP-3060554-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061518-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-30 | — | — | WO | disclosed |
| WO-2015061518-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR1E, POLR1G | MMP1 3144/4885MMP9 2601/4885MMP13 3736/4885 |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR1G, POLR1E | MMP1 3205/4885MMP9 2622/4885MMP13 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.